MAQS advised Oblique Therapeutics on the deal. Oblique Therapeutics AB (publ) completed a rights issue of approximately SEK 53.2 million. Oblique Therapeutics is a privately held...
You must be a Standard 1 Year member to access this content.
MAQS Advokatbyrå has represented Big Akwa AB in the deal. Big Akwa AB and its founders received nearly SEK 3 million in seed capital from Almi...
You must be a Standard 1 Year member to access this content.
MAQS Advokatbyrå advised QuiaPEG Pharmaceuticals on the deal. QuiaPEG Pharmaceuticals Holding AB (publ) has carried out a fully guaranteed issue of units consisting of shares, warrants...
You must be a Standard 1 Year member to access this content.
Maqs advised Luxbright on the deal LUXBRIGHT AB (publ) has completed a fully subscribed rights issue, which will provide Luxbright with issue proceeds amounting to approximately...
You must be a Standard 1 Year member to access this content.
